<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-09-14" updated="2019-12-02">
  <drugbank-id primary="true">DB06795</drugbank-id>
  <name>Mafenide</name>
  <description>Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.</description>
  <cas-number>138-39-6</cas-number>
  <unii>58447S8P4L</unii>
  <average-mass>186.232</average-mass>
  <monoisotopic-mass>186.046298264</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7100</ref-id>
        <pubmed-id>22396671</pubmed-id>
        <citation>Maghsoudi H, Salehi F, Khosrowshahi MK, Baghaei M, Nasirzadeh M, Shams R: Comparison between topical honey and mafenide acetate in treatment of burn wounds. Ann Burns Fire Disasters. 2011 Sep 30;24(3):132-7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>U.S. Patent 2,288,531.</synthesis-reference>
  <indication>Indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.[label]</indication>
  <pharmacodynamics/>
  <mechanism-of-action>The precise mechanism of mafenide is unknown. However, mafenide reduces the bacterial population in the avascular burn tissue and promotes spontaneous heeling of deep burns. </mechanism-of-action>
  <toxicity>Since mafenide is metabolized to a carbonic anhydrase inhibitor, metabolic acidosis could occur. </toxicity>
  <metabolism>Metabolized to a carbonic anhydrase inhibitor.</metabolism>
  <absorption>Mafenide is absorbed through devascularized areas into the systemic circulation following topical administration.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination>Renalâ€”Metabolite rapidly excreted in urine in high concentrations; however, the parent compound has not been detected in urine. </route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.</description>
    <direct-parent>Benzenesulfonamides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Benzenesulfonamides</subclass>
    <alternative-parent>Aminosulfonyl compounds</alternative-parent>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Benzenesulfonyl compounds</alternative-parent>
    <alternative-parent>Benzylamines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Organosulfonamides</alternative-parent>
    <alternative-parent>Phenylmethylamines</alternative-parent>
    <substituent>Amine</substituent>
    <substituent>Aminosulfonyl compound</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Benzenesulfonamide</substituent>
    <substituent>Benzenesulfonyl group</substituent>
    <substituent>Benzylamine</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic sulfonic acid or derivatives</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Organosulfonic acid amide</substituent>
    <substituent>Organosulfonic acid or derivatives</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Phenylmethylamine</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Sulfonyl</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001076</drugbank-id>
      <name>Mafenide Acetate</name>
      <unii>RQ6LP6Z0WY</unii>
      <cas-number>13009-99-9</cas-number>
      <inchikey>UILOTUUZKGTYFQ-UHFFFAOYSA-N</inchikey>
      <average-mass>246.28</average-mass>
      <monoisotopic-mass>246.067428113</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="iupac">4-(aminomethyl)benzenesulfonamide</synonym>
    <synonym language="english" coder="">4-Homosufanilamide</synonym>
    <synonym language="english" coder="">Bensulfamide</synonym>
    <synonym language="english" coder="inn/usan">Mafenide</synonym>
    <synonym language="english" coder="">Maphenidum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Mafenide acetate</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 g/1</strength>
      <route>Topical</route>
      <fda-application-number>ANDA201511</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mafenide Acetate</name>
      <labeller>Riconpharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>51125-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-31</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 g/1</strength>
      <route>Topical</route>
      <fda-application-number>ANDA206716</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mafenide Acetate</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 g/1</strength>
      <route>Topical</route>
      <fda-application-number>ANDA206716</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sulfamylon</name>
      <labeller>Mylan Institutional Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51079-623</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>85 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA016763</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sulfamylon</name>
      <labeller>Mylan Bertek Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62794-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-05</started-marketing-on>
      <ended-marketing-on>2007-03-05</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 g/1</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sulfamylon</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-624</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 g/1</strength>
      <route>Topical</route>
      <fda-application-number>NDA019832</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sulfamylon Cream - 8.5%</name>
      <labeller>Mylan Bertek Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02215802</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-03-07</started-marketing-on>
      <ended-marketing-on>2008-11-20</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Mafenide Acetate</name>
      <ingredients>Mafenide</ingredients>
    </mixture>
    <mixture>
      <name>Mafenide acetate</name>
      <ingredients>Mafenide</ingredients>
    </mixture>
    <mixture>
      <name>Sulfamylon</name>
      <ingredients>Mafenide</ingredients>
    </mixture>
    <mixture>
      <name>Sulfamylon</name>
      <ingredients>Mafenide</ingredients>
    </mixture>
    <mixture>
      <name>Mafenide Acetate</name>
      <ingredients>Mafenide</ingredients>
    </mixture>
    <mixture>
      <name>Sulfamylon</name>
      <ingredients>Mafenide</ingredients>
    </mixture>
    <mixture>
      <name>Sulfamylon Cream - 8.5%</name>
      <ingredients>Mafenide</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents, Local</category>
      <mesh-id>D000891</mesh-id>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Drugs that are Mainly Renally Excreted</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gynecological Antiinfectives and Antiseptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Methemoglobinemia Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sulfonamide Antibacterial</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sulfonamides</category>
      <mesh-id>D013449</mesh-id>
    </category>
    <category>
      <category>Sulfones</category>
      <mesh-id>D013450</mesh-id>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Gram negative and gram positive bacteria</affected-organism>
    <affected-organism>Bacteria</affected-organism>
    <affected-organism>Pseudomonas aeruginosa</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Topical</route>
      <strength>50 g/1</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>85 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="G01AE10">
      <level code="G01AE">Sulfonamides</level>
      <level code="G01A">ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS</level>
      <level code="G01">GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="D06BA03">
      <level code="D06BA">Sulfonamides</level>
      <level code="D06B">CHEMOTHERAPEUTICS FOR TOPICAL USE</level>
      <level code="D06">ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>5jnc</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06795.pdf?1400780957</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00750</drugbank-id>
      <name>Prilocaine</name>
      <description>The risk or severity of methemoglobinemia can be increased when Mafenide is combined with Prilocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Mafenide.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.37</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.18e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.54</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-(aminomethyl)benzene-1-sulfonamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>emilene</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>186.232</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>186.046298264</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NCC1=CC=C(C=C1)S(N)(=O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C7H10N2O2S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>TYMRLRRVMHJFTF-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>86.18</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>46.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>18.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>10.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>177</value>
      <source>U.S. Patent 2,288,531.</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11904</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>6633</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>3998</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310264891</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07106</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02351</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>3858</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>10860</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>6LH</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Mafenide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL419</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/international/Mafenide.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0003628</id>
      <name>Carbonic anhydrase 6</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18322</ref-id>
            <pubmed-id>22974493</pubmed-id>
            <citation>Demirdag R, Comakli V, Senturk M, Ekinci D, Irfan Kufrevioglu O, Supuran CT: Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity. Bioorg Med Chem. 2013 Mar 15;21(6):1522-5. doi: 10.1016/j.bmc.2012.08.018. Epub 2012 Aug 24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P23280" source="Swiss-Prot">
        <name>Carbonic anhydrase 6</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Reversible hydration of carbon dioxide. Its role in saliva is unknown.</specific-function>
        <gene-name>CA6</gene-name>
        <locus/>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-17</signal-regions>
        <theoretical-pi/>
        <molecular-weight>35366.615</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1380</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P23280</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CAH6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>4.2.1.1</synonym>
          <synonym>CA-VI</synonym>
          <synonym>Carbonate dehydratase VI</synonym>
          <synonym>Carbonic anhydrase VI</synonym>
          <synonym>Salivary carbonic anhydrase</synonym>
          <synonym>Secreted carbonic anhydrase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009331|Carbonic anhydrase 6
MRALVLLLSLFLLGGQAQHVSDWTYSEGALDEAHWPQHYPACGGQRQSPINLQRTKVRYN
PSLKGLNMTGYETQAGEFPMVNNGHTVQISLPSTMRMTVADGTVYIAQQMHFHWGGASSE
ISGSEHTVDGIRHVIEIHIVHYNSKYKSYDIAQDAPDGLAVLAAFVEVKNYPENTYYSNF
ISHLANIKYPGQRTTLTGLDVQDMLPRNLQHYYTYHGSLTTPPCTENVHWFVLADFVKLS
RTQVWKLENSLLDHRNKTIHNDYRRTQPLNHRVVESNFPNQEYTLGSEFQFYLHKIEEIL
DYLRRALN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019449|Carbonic anhydrase 6 (CA6)
ATGAGGGCCCTGGTGCTTCTGCTGTCCCTGTTCCTGCTGGGTGGCCAGGCCCAGCATGTG
TCTGACTGGACCTACTCAGAAGGGGCACTGGACGAAGCGCACTGGCCACAGCACTACCCC
GCCTGTGGGGGCCAGAGACAGTCGCCTATCAACCTACAGAGGACGAAGGTGCGGTACAAC
CCCTCCTTGAAGGGGCTCAATATGACAGGCTATGAGACCCAGGCAGGGGAGTTCCCCATG
GTCAACAATGGCCACACAGTGCAGATCAGCCTGCCCTCCACCATGCGCATGACAGTGGCT
GACGGCACTGTATACATAGCCCAGCAGATGCACTTTCACTGGGGAGGTGCGTCCTCGGAG
ATCAGCGGCTCTGAGCACACCGTGGACGGGATCAGACATGTGATCGAGATTCACATTGTT
CACTACAATTCTAAATACAAGAGCTATGATATAGCCCAAGATGCGCCGGATGGTTTGGCT
GTACTGGCAGCCTTCGTTGAGGTGAAGAATTACCCTGAAAACACTTATTACAGCAACTTC
ATTTCTCATCTGGCCAACATCAAGTACCCAGGACAAAGAACAACCCTGACTGGCCTTGAC
GTTCAGGACATGCTGCCCAGGAACCTCCAGCACTACTACACCTACCATGGCTCACTCACC
ACGCCTCCCTGCACTGAGAACGTCCACTGGTTTGTGCTGGCAGATTTTGTCAAGCTCTCC
AGGACACAGGTTTGGAAGCTGGAGAATTCCTTACTGGATCACCGCAACAAGACCATCCAC
AACGATTACCGCAGGACCCAGCCCCTGAACCACAGAGTGGTGGAATCCAACTTCCCGAAT
CAGGAATACACTCTAGGCTCTGAATTCCAGTTTTACCTACATAAGATTGAGGAAATTCTT
GACTACTTAAGAAGAGCATTGAACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00194</identifier>
            <name>Carb_anhydrase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carbonate dehydratase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bicarbonate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of chemical stimulus involved in sensory perception of bitter taste</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>one-carbon metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>